文献速递免疫规划传染病防控与疫情报告

鼻内加强免疫MVA-AE可增强新生儿期BCG接种小鼠的肺部免疫与抗结核保护

Intranasal boosting with MVA encoding secreted mycobacterial proteins Ag85A and ESAT-6 generates strong pulmonary immune responses and protection against M. tuberculosis in mice given BCG as neonates.
PubMed 文献 · Vaccine · 2021-02-23

本研究构建表达分泌型结核分枝杆菌蛋白Ag85A和ESAT-6的改良痘苗病毒安卡拉株(MVA-AE),评估其作为新生儿期皮下接种BCG后黏膜加强疫苗的免疫原性和保护效果。鼻内给予MVA-AE可在小鼠肺部诱导针对Ag85A和ESAT-6的CD4+和CD8+ T细胞应答,经BCG初免后这些应答显著增强。BCG/MVA-AE组在气溶胶攻击结核分枝杆菌H37Rv后肺部菌载量显著低于对照MVA加强组或仅BCG组。

要点

  • 鼻内MVA-AE加强可增强新生儿期BCG初免小鼠肺部Ag85A和ESAT-6特异性CD4+和CD8+ T细胞应答。
  • 加强后肺部T细胞可分泌IFNγ、IL-2和IL-17,并诱导针对ESAT-6的多功能CD4+ T细胞。
  • BCG/MVA-AE组在结核分枝杆菌H37Rv气溶胶攻击后肺部菌载量显著降低。

核心结论

  • 鼻内递送MVA-AE可加强新生儿期BCG诱导的肺部Th1和Th17免疫,并提高其对结核分枝杆菌感染的保护效果。

研究设计与样本

  • 研究构建表达Ag85A和ESAT-6的MVA-AE疫苗,在新生期皮下接种BCG的小鼠中评估鼻内加强的免疫原性与保护效力。
  • 保护效力评估采用结核分枝杆菌H37Rv气溶胶攻击模型,比较BCG/MVA-AE组、BCG加对照MVA加强组和仅BCG组的肺部菌载量。

主要发现

  • 鼻内MVA-AE可在年轻成年小鼠肺部诱导针对Ag85A和ESAT-6的CD4+和CD8+ T细胞应答。
  • 新生儿期BCG初免后鼻内MVA-AE加强组(BCG/MVA-AE)肺部Ag85A、ESAT-6和PPD特异性CD4+和CD8+ T细胞数量及其分泌IFNγ、IL-2和IL-17的能力显著增强。
  • MVA-AE加强产生针对ESAT-6的多功能肺部CD4+ T细胞,并升高Ag85A特异性循环抗体应答。
  • 结核分枝杆菌H37Rv气溶胶攻击后,BCG/MVA-AE组肺部菌载量显著低于BCG加对照MVA加强组和仅BCG组。

临床怎么用

  • 提示新生儿期BCG接种后采用鼻内MVA-AE加强可能增强肺部局部Th1/Th17免疫和抗结核保护,为疫苗策略提供临床前依据。

局限性

  • 研究为小鼠模型,免疫原性和保护效力结果需在人体中进一步验证。
  • 原文未报告样本量、具体菌载量数值、统计P值或置信区间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bacille-Calmette-Guerin (BCG) has variable efficacy as an adult tuberculosis (TB) vaccine but can reduce the incidence and severity of TB infection in humans. We have engineered modified vaccinia Ankara (MVA) strain vaccine constructs to express the secreted mycobacterial proteins Ag85A and ESAT-6 (MVA-AE) and evaluated their immunogenicity and protective efficacy as mucosal booster vaccines for BCG given subcutaneously in early life. Intranasal delivery of MVA-AE to young adult mice induced CD4+ and CD8+ T cell responses to both Ag85A and ESAT-6 in lung mucosae. These responses were markedly enhanced in mice that had been primed neonatally with BCG prior to intranasal MVA-AE immunization (BCG/MVA-AE), as evidenced by numbers of pulmonary Ag85A-, ESAT-6-, and PPD-specific CD4+ and CD8+ T cells and by their capacity to secrete multiple antimicrobial factors, including IFNγ, IL-2 and IL-17. Moreover, MVA-AE boosting generated multifunctional lung CD4+ T cells responding to ESAT-6, which were not, as expected, detected in control mice given BCG, and elevated Ag85A-specific circulating antibody responses. After aerosol challenge with M. tuberculosis H37Rv (Mtb), the BCG/MVA-AE group had significantly reduced mycobacterial burden in the lungs, compared with either BCG primed mice boosted with control MVA or mice given only BCG. These data indicate that intranasal delivery of MVA-AE can boost BCG-induced Th1 and Th17-based immunity locally in the lungs and improve the protective efficacy of neonatally-administered BCG against M. tuberculosis infection.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Khanna M, Rady H, Dai G, et al. Intranasal boosting with MVA encoding secreted mycobacterial proteins Ag85A and ESAT-6 generates strong pulmonary immune responses and protection against M. tuberculosis in mice given BCG as neonates. Vaccine. 2021. PMID: 33632562. doi:10.1016/j.vaccine.2021.01.071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。